ABCL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Abcellera Biologics Inc (ABCL) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has shown positive revenue growth and better-than-expected earnings, the stock lacks clear bullish signals in technical indicators, options sentiment, and trading trends. Additionally, the financial performance still reflects significant net income losses, and there are no strong catalysts or signals to suggest immediate upside potential.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral, and the moving averages remain bearish (SMA_200 > SMA_20 > SMA_5). The stock price is close to resistance levels (R1: 3.501), suggesting limited immediate upside potential.
The company reported a better-than-expected Q4 loss and significant revenue growth (up 788.18% YoY). Gross margins remain strong at 100%.
Net income dropped significantly (-73.85% YoY), and EPS declined (-75.00% YoY). The stock lacks strong trading trends from hedge funds or insiders, and no recent congress trading data is available. Additionally, the stock's long-term trend remains bearish based on moving averages.
In Q4 2025, revenue surged by 788.18% YoY to $44.85 million. However, net income dropped to -$8.94 million (-73.85% YoY), and EPS fell to -$0.03 (-75.00% YoY). Despite the revenue growth, profitability remains a concern.
No recent analyst rating or price target changes are available. Wall Street sentiment appears neutral with no strong buy or sell recommendations.
